Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

17alpha-hydroxylase/17,20-lyase (p450(17alpha)) inhibitors in the treatment of prostate cancer: a review.

Owen CP.

Anticancer Agents Med Chem. 2009 Jul;9(6):613-26. Review.

PMID:
19601745
2.

Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.

Leroux F.

Curr Med Chem. 2005;12(14):1623-9. Review.

PMID:
16022662
3.

CYP17A1: a biochemistry, chemistry, and clinical review.

Porubek D.

Curr Top Med Chem. 2013;13(12):1364-84. Review.

PMID:
23688130
4.

Inhibition of CYP 17, a new strategy for the treatment of prostate cancer.

Hartmann RW, Ehmer PB, Haidar S, Hector M, Jose J, Klein CD, Seidel SB, Sergejew TF, Wachall BG, Wächter GA, Zhuang Y.

Arch Pharm (Weinheim). 2002 Apr;335(4):119-28. Review.

PMID:
12112031
5.

Inhibitors of steroidal cytochrome p450 enzymes as targets for drug development.

Baston E, Leroux FR.

Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):31-58. Review.

PMID:
18221052
6.
7.

[Advances in the study of steroidal inhibitors of cytochrome P45017alpha].

Du JJ, Chen HL, Li YC.

Yao Xue Xue Bao. 2013 Jan;48(1):25-31. Review. Chinese.

PMID:
23600137
8.

CYP17 inhibitors for prostate cancer treatment--an update.

Moreira VM, Salvador JA, Vasaitis TS, Njar VC.

Curr Med Chem. 2008;15(9):868-99. Review.

PMID:
18473796
9.

Targeting CYP17: established and novel approaches in prostate cancer.

Yap TA, Carden CP, Attard G, de Bono JS.

Curr Opin Pharmacol. 2008 Aug;8(4):449-57. doi: 10.1016/j.coph.2008.06.004. Epub 2008 Jul 28. Review.

PMID:
18619560
10.

P450-dependent enzymes as targets for prostate cancer therapy.

De Coster R, Wouters W, Bruynseels J.

J Steroid Biochem Mol Biol. 1996 Jan;56(1-6 Spec No):133-43. Review.

PMID:
8603034
11.

Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases.

Salvador JA, Pinto RM, Silvestre SM.

J Steroid Biochem Mol Biol. 2013 Sep;137:199-222. doi: 10.1016/j.jsbmb.2013.04.006. Epub 2013 May 18. Review.

PMID:
23688836
12.

CYP17 inhibitors for prostate cancer therapy.

Vasaitis TS, Bruno RD, Njar VC.

J Steroid Biochem Mol Biol. 2011 May;125(1-2):23-31. doi: 10.1016/j.jsbmb.2010.11.005. Epub 2010 Nov 17. Review.

13.

Inhibitors of enzymes of androgen biosynthesis: cytochrome P450(17) alpha and 5 alpha-steroid reductase.

Jarman M, Smith HJ, Nicholls PJ, Simons C.

Nat Prod Rep. 1998 Oct;15(5):495-512. Review. No abstract available.

PMID:
9807812
14.

[CYP17A1 inhibitors in prostate cancer: mechanisms of action independent of the androgenic pathway].

Audenet F, Murez T, Ripert T, Villers A, Neuzillet Y.

Prog Urol. 2013 Oct;23 Suppl 1:S9-15. doi: 10.1016/S1166-7087(13)70041-1. Review. French.

PMID:
24314739
15.

CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.

Yin L, Hu Q.

Nat Rev Urol. 2014 Jan;11(1):32-42. doi: 10.1038/nrurol.2013.274. Epub 2013 Nov 26. Review.

PMID:
24276076
16.

Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer.

Ferraldeschi R, Sharifi N, Auchus RJ, Attard G.

Clin Cancer Res. 2013 Jul 1;19(13):3353-9. doi: 10.1158/1078-0432.CCR-12-0931. Epub 2013 Mar 7. Review.

17.

[Research and development of hormone-related anti-prostate cancer drugs-17, 20-lyase inhibitors for prostate cancer].

Hara T.

Nihon Yakurigaku Zasshi. 2010 Oct;136(4):192-7. Review. Japanese. No abstract available.

PMID:
20948153

Supplemental Content

Support Center